US Oncology Market to Reach $212 Billion by 2034, Driven by Precision Therapies.

miércoles, 24 de diciembre de 2025, 6:05 am ET1 min de lectura
CRBU--
GTBP--
LYEL--
NRIX--
SLS--

The US oncology market is expected to grow from $81 billion in 2025 to $212 billion by 2034, driven by a shift towards targeted therapies and immunotherapies that offer precision mechanisms for combating resistant cancer forms. Companies such as GT Biopharma, Lyell Immunopharma, Caribou Biosciences, SELLAS Life Sciences, and Nurix Therapeutics are poised to benefit from this trend, with the pancreatic cancer precision medicine market predicted to surge from $823 million in 2025 to $4.03 billion by 2034.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios